T1	Condition 0 17	Contraindications
T2	Drug 21 34	empagliflozin
T3	Drug 36 47	Sitagliptin
*	OR T2 T3
T4	Scope 21 47	empagliflozin, Sitagliptin
R1	Has_scope Arg1:T1 Arg2:T4	
T5	Drug 49 64	DPP4 inhibitors
T6	Drug 68 116	Sodium-glucose cotransporter-2(SGLT2) inhibitors
T7	Temporal 117 144	within the previous 4 weeks
*	OR T5 T6
T8	Scope 49 116	DPP4 inhibitors or Sodium-glucose cotransporter-2(SGLT2) inhibitors
R2	Has_temporal Arg1:T8 Arg2:T7	
T9	Drug 146 153	Insulin
T10	Procedure 164 172	diabetes
R3	AND Arg1:T10 Arg2:T9	
T11	Condition 174 194	Poor glucose control
T12	Measurement 196 201	HbA1C
T13	Value 201 206	>10 %
R4	Has_value Arg1:T12 Arg2:T13	
T14	Scope 196 206	HbA1C>10 %
R5	Subsumes Arg1:T11 Arg2:T14	
T15	Condition 209 232	Acute coronary syndrome
T16	Device 234 239	Stent
T17	Procedure 240 249	placement
R6	AND Arg1:T17 Arg2:T16	
T18	Temporal 250 278	within the previous 6 months
R7	Has_temporal Arg1:T17 Arg2:T18	
T19	Temporal 326 354	within the previous 6 months
T20	Procedure 289 325	coronary artery bypass graft surgery
R8	Has_temporal Arg1:T20 Arg2:T19	
T21	Temporal 280 288	Previous
R9	Has_temporal Arg1:T20 Arg2:T21	
T22	Procedure 364 381	revascularization
T23	Temporal 382 397	within 6 months
R10	Has_temporal Arg1:T22 Arg2:T23	
T24	Mood 356 363	Planned
R11	Has_mood Arg1:T22 Arg2:T24	
T25	Condition 399 412	Heart failure
T26	Drug 423 437	loop diuretics
R12	AND Arg1:T25 Arg2:T26	
T27	Condition 446 474	left ventricular hypertrophy
T28	Qualifier 439 445	Severe
R13	Has_qualifier Arg1:T27 Arg2:T28	
T29	Measurement 476 514	left ventricular septal wall thickness
T30	Value 515 521	> 13mm
*	OR T29 T30
T31	Scope 439 474	Severe left ventricular hypertrophy
T32	Scope 476 521	left ventricular septal wall thickness > 13mm
R14	Subsumes Arg1:T31 Arg2:T32	
T33	Qualifier 524 535	Significant
T34	Condition 536 549	renal disease
T35	Measurement 564 584	creatinine clearance
T36	Value 588 599	< 30 ml/min
R15	Has_value Arg1:T35 Arg2:T36	
R16	Has_qualifier Arg1:T34 Arg2:T33	
T37	Scope 524 549	Significant renal disease
T38	Scope 564 599	creatinine clearance of < 30 ml/min
R17	Subsumes Arg1:T37 Arg2:T38	
T39	Condition 602 617	Hepatic disease
T40	Condition 621 646	biliary tract obstruction
T41	Condition 663 687	hepatic enzyme elevation
T42	Qualifier 651 662	significant
R18	Has_qualifier Arg1:T41 Arg2:T42	
*	OR T39 T40 T41 T47
T43	Measurement 689 709	alanine transaminase
T44	Measurement 713 739	Aspartate Aminotransferase
T45	Value 740 771	> 3 times upper limit of normal
*	OR T43 T44
T46	Scope 689 739	alanine transaminase or Aspartate Aminotransferase
R19	Has_value Arg1:T46 Arg2:T45	
T47	Scope 689 771	alanine transaminase or Aspartate Aminotransferase > 3 times upper limit of normal
T48	Device 774 793	Radiopaque material
T49	Qualifier 811 821	chest wall
R20	Has_qualifier Arg1:T48 Arg2:T49	
T50	Procedure 867 888	adenosine stress test
T51	Condition 847 863	Contraindication
R21	AND Arg1:T51 Arg2:T50	
T52	Post-eligibility 890 1113	Any clinically significant abnormality identified at the screening visit, physical examination, laboratory tests, or electrocardiogram which, in the judgment of the Investigator, would preclude safe completion of the study.
T53	Condition 1125 1133	pregnant
T54	Condition 1137 1151	breast-feeding
T55	Condition 1155 1178	child-bearing potential
*	OR T55 T54 T53
T56	Observation 1180 1204	Expected life expectancy
T57	Value 1205 1213	< 1 year
R22	Has_value Arg1:T56 Arg2:T57	
T58	Non-query-able 1215 1298	Unwillingness or inability to comply with the procedures described in this protocol
